Navigation Links
Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
Date:7/30/2010

veloping ANA598, a direct-acting antiviral or DAA, for the treatment of hepatitis C. In an ongoing Phase II study, the Company has completed 12 weeks of dosing ANA598 added to current standard of care. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended June 30, 2010.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... fundamental traits of a,tumor – how it avoids ... according to researchers from the,University of Southern California. ... cancers, indicate that,a technique for determining a tumor’s ... cancers. , ,In the July 1 issue ...
... - Nymox,Pharmaceutical Corporation (NASDAQ: NYMX) today announced ... of NX-1207 for,benign prostatic hyperplasia (BPH) will ... the American Urological Association Meeting in,Boston in ... clinical,research investigators from U.S. clinical trials of ...
Cached Medicine Technology:Researchers Discover Method for Identifying How Cancer Evades the,Immune System 2Researchers Discover Method for Identifying How Cancer Evades the,Immune System 3Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting 2
(Date:8/28/2015)... IL (PRWEB) , ... August 28, 2015 , ... With ... benefit concert returned for the second year to the Adams County Fairgrounds in Mendon, ... was held to raise money to support music education in the underfunded school districts ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... from beginning to end. , Businesses benefit greatly from having the ability to track ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Veterans Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery ... first and only nonsurgical product approved by the Food and Drug Administration to eliminate ... and Dr. William Koenig are among the premier cosmetic surgeons in Rochester ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... closed, American cardiologists say , , WEDNESDAY, July 2 (HealthDay ... to adrenaline did not improve survival among people who ... American cardiologists said the finding does not rule out ... report comes from a group, primarily French, that several ...
... 2 Hanger Orthopedic,Group, Inc. (NYSE: HGR ... Poor,s,Rating Services revised its outlook for Hanger Orthopedic ... Hanger,s corporate credit,rating at "B." "The outlook revision ... an improved financial risk profile," said,Standard & Poor,s ...
... medicine specialist, John Albright, MD, will join three other physicians as ... Fame inductee. , ... Orlando, Florida (PRWEB) July 2, ... will join three other physicians as a 2008 American Orthopaedic ...
... Ambulatory Services of,America, Inc. announced the acquisition of ... from Affiliated Hospitals Dialysis Center.,Affiliated Hospitals Dialysis Center ... and St. John,s Mercy Health System. Prior,to the ... 300 patients,through the three outpatient dialysis centers and ...
... Larry Minnix, President & CEO, American Association of,Homes ... of the Medicare Therapy,Caps Exceptions Process, WASHINGTON, ... Minnix, President & CEO, American Association of Homes ... the Medicare Therapy Caps,Exceptions Process:, "Medicare beneficiaries ...
... Ambulatory Services of,America, Inc. announced the formation of ... to provide outpatient radiation oncology services. ROSA,of North ... Radiation,Oncology Services of America, and some of the ... North Dallas will own and operate Northpoint,Cancer Center ...
Cached Medicine News:Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 2Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3Health News:Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri 2Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2
3 mm, 130 degree upwards cutting, detachable....
Aaron 950 is a high frequency desiccator with cut....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: